AVROBIO appoints three executives
Nerissa Kreher joins as Chief Medical Officer for Rare Diseases.
Dr. Kreher is a pediatric endocrinologist with deep academic, clinical research and biotechnology industry experience.
She has held leadership roles in both clinical development and medical affairs within private start-up biotechnology and large biotechnology companies focused on rare diseases.
Most recently Dr. Kreher was the Global Head of Clinical and Medical Affairs at Zafgen. She held roles of increasing responsibility at Shire, Alexion, Enobia Pharma, Genzyme and EMD Serono.
Dr. Kreher received a BA from the University of North Carolina, an MD from East Carolina University School of Medicine, an MS in Clinical Research from Indiana University and an Executive MBA from Northeastern University.
Kathryn McNaughton joins as Senior Vice President of Portfolio and Program Management.
Dr. McNaughton has 20 years of experience in the biotech industry encompassing R&D, Program Management and assessment of business development opportunities.
Dr. McNaughton was previously Vice President, R&D Pipeline Program Management at Synageva, and held roles of increasing responsibility at Shire and Praecis Pharmaceuticals.
Dr. McNaughton earned a PhD in Chemistry from Princeton University and a BS in Chemistry from Monmouth University.
Richard Pfeifer joins as Director of Preclinical Development.
Dr. Pfeifer is a board-certified toxicologist. He was previously Head of Toxicology at Shire, and held roles of increasing responsibility at Wyeth Research, Ciba-Geigy Corp., and in the contract services industry.
Dr. Pfeifer was also an Assistant Professor of Toxicology at Purdue University. He pursued postdoctoral fellowships in Immunotoxicology at the Chemical Industry Institute of Toxicology and the National Institute of Environmental Health Sciences.
Dr. Pfeifer received a BS in Biology from Bucknell University and a PhD in Pharmacology from the University of Rochester School of Medicine & Dentistry.